These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 25841041)

  • 41. Antipsychotics for negative and positive symptoms of schizophrenia: dose-response meta-analysis of randomized controlled acute phase trials.
    Sabe M; Zhao N; Crippa A; Kaiser S
    NPJ Schizophr; 2021 Sep; 7(1):43. PubMed ID: 34518532
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lumateperone (Caplyta) for schizophrenia.
    Med Lett Drugs Ther; 2020 Jul; 62(1603):113-116. PubMed ID: 32728011
    [No Abstract]   [Full Text] [Related]  

  • 43. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
    Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW
    Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.
    Edwards NC; Locklear JC; Rupnow MF; Diamond RJ
    Pharmacoeconomics; 2005; 23 Suppl 1():75-89. PubMed ID: 16416763
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Antipsychotic Treatment of the Adult Patient in the Acute Phase of Schizophrenia].
    Bohórquez Peñaranda A; Gómez Restrepo C; García Valencia J; Jaramillo González LE; de la Hoz AM; Arenas Á; Tamayo Martínez N
    Rev Colomb Psiquiatr; 2014; 44 Suppl 1():13-28. PubMed ID: 26576459
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2009 Aug; 63(8):1237-48. PubMed ID: 19624791
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
    Soares-Weiser K; Béchard-Evans L; Lawson AH; Davis J; Ascher-Svanum H
    Eur Neuropsychopharmacol; 2013 Feb; 23(2):118-25. PubMed ID: 22633617
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fluphenazine (oral) versus atypical antipsychotics for schizophrenia.
    Sampford JR; Sampson S; Li BG; Zhao S; Xia J; Furtado VA
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD010832. PubMed ID: 27370402
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A different insight in hair analysis: Simultaneous measurement of antipsychotic drugs and metabolites in the protein and melanin fraction of hair from criminal justice patients.
    Ramírez Fernández MDM; Baumgartner WA; Wille SMR; Farabee D; Samyn N; Baumgartner AM
    Forensic Sci Int; 2020 Jul; 312():110337. PubMed ID: 32450478
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A meta-analysis of the efficacy of second-generation antipsychotics.
    Davis JM; Chen N; Glick ID
    Arch Gen Psychiatry; 2003 Jun; 60(6):553-64. PubMed ID: 12796218
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risperidone versus other atypical antipsychotic medication for schizophrenia.
    Gilbody SM; Bagnall AM; Duggan L; Tuunainen A
    Cochrane Database Syst Rev; 2000; (3):CD002306. PubMed ID: 10908551
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Newer atypical antipsychotic medication versus clozapine for schizophrenia.
    Tuunainen A; Wahlbeck K; Gilbody SM
    Cochrane Database Syst Rev; 2000; (2):CD000966. PubMed ID: 10796559
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Estimating dopamine D₂ receptor occupancy for doses of 8 antipsychotics: a meta-analysis.
    Lako IM; van den Heuvel ER; Knegtering H; Bruggeman R; Taxis K
    J Clin Psychopharmacol; 2013 Oct; 33(5):675-81. PubMed ID: 23948784
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Electroencephalogram Modifications Associated With Atypical Strict Antipsychotic Monotherapies.
    Dias Alves M; Micoulaud-Franchi JA; Simon N; Vion-Dury J
    J Clin Psychopharmacol; 2018 Dec; 38(6):555-562. PubMed ID: 30247179
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 57. All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis.
    Beasley CM; Stauffer VL; Liu-Seifert H; Taylor CC; Dunayevich E; Davis JM
    J Clin Psychopharmacol; 2007 Jun; 27(3):252-8. PubMed ID: 17502771
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions.
    Raggi MA; Mandrioli R; Sabbioni C; Pucci V
    Curr Med Chem; 2004 Feb; 11(3):279-96. PubMed ID: 14965232
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia.
    Citrome L
    Expert Opin Pharmacother; 2012 Aug; 13(11):1545-73. PubMed ID: 21999805
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia.
    McCue RE; Waheed R; Urcuyo L; Orendain G; Joseph MD; Charles R; Hasan SM
    Br J Psychiatry; 2006 Nov; 189():433-40. PubMed ID: 17077434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.